Skip to main content
main-content
Top

12-07-2022 | Pancreatic cancer | Adis Journal Club | Article

Oncology and Therapy

Minimally Invasive Pancreatoduodenectomy: Contemporary Practice, Evidence, and Knowledge Gaps

share
SHARE
print
PRINT
insite
SEARCH

Authors: Jacob Ghotbi, Mushegh Sahakyan, Kjetil Søreide, Åsmund Avdem Fretland, Bård Røsok, Tore Tholfsen, Anne Waage, Bjørn Edwin, Knut Jørgen Labori, Sheraz Yaqub & Dyre Kleive

Abstract

Minimally invasive pancreatoduodenectomy has gained popularity throughout the last decade. For laparoscopic pancreatoduodenectomy, some high-level evidence exists, but with conflicting results. There are currently no published randomized controlled trials comparing robotic and open pancreatoduodenectomy. Comparative long-term data for patients with pancreatic ductal adenocarcinoma is lacking to date. Based on the existing evidence, current observed benefits of minimally invasive pancreatoduodenectomy over open pancreatoduodenectomy seem scarce, but retrospective data indicate the safety of these procedures in selected patients. As familiarity with the robotic platform increases, studies have shown an expansion in indications, also including patients with vascular involvement and even indicating favorable results in patients with obesity and high-risk morphometric features. Several ongoing randomized controlled trials aim to investigate potential differences in short- and long-term outcomes between minimally invasive and open pancreatoduodenectomy. Their results are much awaited.

View the full open access article

Key Summary Points 

Minimally invasive pancreatoduodenectomy has gained popularity throughout the last decade.

For laparoscopic pancreatoduodenectomy, some high-level evidence exists with conflicting results.

Familiarity with the robotic platform shows an expansion in indications and there has been an increased awareness of structured training and patient selection for minimally invasive pancreatoduodenectomy.

Comparative long-term data for patients with pancreatic ductal adenocarcinoma are lacking to date, but several ongoing randomized controlled trials exist.

share
SHARE
print
PRINT